China's NMPA Approves Satri-Cel, the World's First CAR-T Therapy for a Solid Tumor, in Advanced Gastric Cancer
CARsgen's Claudin18.2-directed CAR-T satri-cel won Chinese approval for pretreated gastric cancer, becoming the first CAR-T cleared for any solid tumor.
Overview
China’s National Medical Products Administration has approved satricabtagene autoleucel, known as satri-cel, making it the first CAR T-cell therapy cleared anywhere in the world for a solid tumor. CARsgen Therapeutics announced the approval on June 22, 2026, and described satri-cel as “the world’s first approved CAR T-cell therapy product for solid tumors,” according to the company’s press release. Coverage by HealthCare Middle East & Africa likewise noted that the decision “makes satri-cel the first CAR-T therapy anywhere in the world to receive regulatory approval for a solid tumor indication.”
CAR-T therapies — patient-derived T cells re-engineered to recognize and attack cancer — have reshaped the treatment of blood cancers but have repeatedly failed against solid tumors, whose dense, immunosuppressive microenvironments resist cell-based attack.
What We Know
The approval covers patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy, per CARsgen. Satri-cel targets Claudin18.2, described by HealthCare Middle East & Africa as “a protein that is highly expressed in gastric cancers but is limited in normal tissues.”
The approval rests on the CT041-ST-01 trial, a randomised, open-label, phase 2 study. According to the trial abstract published in The Lancet and indexed on PubMed, 156 patients were randomly allocated to the satri-cel group (n=104) or a treatment-of-physician’s-choice group (n=52) in a 2:1 ratio, with progression-free survival assessed by an independent review committee as the primary endpoint.
The study met that endpoint. Median progression-free survival “was 3·25 months (95% CI 2·86-4·53) in the satri-cel group and 1·77 months (1·61-2·04) in the TPC group (hazard ratio 0·37 [95% CI 0·24-0·56])” with p<0.0001, per PubMed. On overall survival, patients on satri-cel reached a median of 7.92 months versus 5.49 months for those on standard treatment, according to HealthCare Middle East & Africa.
The safety profile reflected the intensity typical of CAR-T therapy. Cytokine release syndrome occurred in 84 of 88 patients (95%) in the satri-cel group, and grade 3 or higher treatment-emergent adverse events occurred in 87 of 88 patients (99%), per the trial abstract on PubMed. The trial investigators concluded that satri-cel “resulted in a significant improvement in progression-free survival, with a manageable safety profile.”
CARsgen framed the milestone as a turning point for the field. “The approval and launch of satri-cel is an important milestone event marking the advancement of CAR-T cell therapy from hematologic malignancies to solid tumors,” said founder, chairman of the board, chief executive officer, and chief scientific officer Dr. Zonghai Li, as quoted in the company’s press release. On commercial rollout, HealthCare Middle East & Africa reported that, according to Dr. Li, “the company expects to begin treating patients within weeks and anticipates receiving approximately 200 treatment orders during the second half of 2026.”
The CT041-ST-01 study was described by CARsgen as “the world’s first randomized controlled clinical study of CAR-T cell therapy for solid tumors,” according to the company’s earlier announcement tied to its publication in The Lancet and presentation at the 2025 ASCO Annual Meeting.
What We Don’t Know
The approval is limited to China; CARsgen’s press release does not detail timelines for regulatory filings in the United States, Europe, or other markets. Pricing for the therapy in China was not disclosed in the sources reviewed. The median survival gains, while statistically significant on progression-free survival, remain measured in months for a heavily pretreated population, and longer-term durability and real-world outcomes beyond the trial cohort are not yet established.
Analysis
For more than a decade, the central question hanging over CAR-T has been whether a technology that cures some blood cancers can be made to work against the solid tumors that account for the overwhelming majority of cancer deaths. Satri-cel’s Chinese approval is the first regulatory answer in the affirmative, but a measured one: the trial’s clearest win was on progression-free survival, with a hazard ratio of 0.37, against a backdrop of near-universal cytokine release syndrome. Whether the approach generalizes beyond Claudin18.2-positive gastric cancer — and beyond China’s regulatory framework — will determine if this proves a one-off or the opening of a new front in cell therapy.